查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1466523

糖尿病神经病变市场：依治疗类型、疾病类型、通路划分 - 全球预测 2024-2030

Diabetic Neuropathy Market by Treatment Type (Drugs, Physiotherapy), Disorder Type (Autonomic Neuropathy, Focal Neuropathy, Peripheral Neuropathy), Distribution channel - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年糖尿病神经病变市场规模为35亿美元，预计2024年将达37.2亿美元，2030年将达54亿美元，复合年增长率为6.37%。

糖尿病神经病变是一种损害神经的疾病，发生在糖尿病患者身上。高血糖（葡萄糖）会损害全身的神经，但糖尿病神经病变最常影响腿部和臀部的神经。对糖尿病神经病变有效治疗、糖尿病诊断的需求不断增长，以及政府的多项措施是糖尿病神经病变市场成长的主要驱动力。此外，人们对糖尿病神经病变认识的提高、医疗保健支出的增加以及医药品研究开发费用的增加都有助于开发治疗糖尿病神经病变的新药物和系统。然而，用于治疗糖尿病神经病变的药物价格昂贵，且替代疗法的可用性可能会限製糖尿病患者的使用。先进药物输送系统的生产和糖尿病神经病变研究的不断增加将导致突破性系统的开发，以有效管理糖尿病神经病变状况，并在预测期内加速患者的使用

主要市场统计
基准年[2023] 35亿美元
预测年份 [2024] 37.2亿美元
预测年份 [2030] 54亿美元
复合年增长率（%） 6.37%

治疗类型：糖尿病神经病变的药物治疗广泛使用药物来缓解疼痛和稳定神经功能。

糖尿病神经病变的药物治疗使用药物来减轻疼痛和稳定神经功能。Pregabalin(Lyrica) 和Gabapentin(Neurontin) 是抗惊厥药，常用于治疗糖尿病神经病变患者的神经疼痛。在鸦片类药物中，曲马多（Ultram）是一种中枢作用的鸦片类镇痛药，用于治疗与糖尿病神经病变相关的中度至重度疼痛。物理治疗又称物理治疗，是一种提升糖尿病神经病变患者的功能能力、缓解疼痛的非药物治疗方法。由经过认证的物理治疗师监督的定期运动和力量训练计划可以帮助糖尿病神经病变患者提高力量、平衡和耐力。通常优选物理治疗以避免副作用和禁忌症。

疾病类型 由于神经病变盛行率增加，糖尿病神经病变优先

自主神经病变影响自主神经系统，自主神经系统控制内臟器官的不自主功能。患有这种疾病的患者会出现心律不整、排尿困难、消化器官系统问题和性功能障碍。根据个人需要，治疗可能包括调节血压和心率的药物、控制胃肠蠕动的药物以及治疗勃起功能障碍的药物。局部神经病变是一种单一神经或一组神经受损的疾病，导致身体特定部位（例如手、脚或躯干）的剧烈疼痛和无力。治疗方法针对根本原因，例如压迫或卡压，包括针对腕管综合症的夹板和矫正器具，以及针对严重病例的手术介入。週边神经病变是最常见的类型，影响手臂、手、脚和腿的神经。症状包括麻木、刺痛、疼痛和虚弱。治疗方法根据个人需求而有所不同，包括非处方止痛药和处方药。近端神经病变主要影响臀部、臀部和大腿的肌肉，症状包括剧烈疼痛和肌肉无力。

通路：网路药局的出现成为糖尿病神经病变治疗药物的便捷通路。

糖尿病神经病变患者喜欢由内分泌科医生、足病医生和糖尿病教育工作者等专家团队提供专门护理的诊所，因为其方便、实惠且可及。该医院为糖尿病神经病变患者提供全面护理，这些患者因感染疾病或溃疡等严重併发症而需要更广泛的治疗或紧急干预。医院拥有擅长治疗复杂病例的设备和多学科团队。网路药局已成为治疗糖尿病神经病变药物（如止痛药、抗惊厥药和抗忧郁症）的便捷通路。网路药局受到患者的青睐，因为与零售药局相比，它们更容易使用，有更谨慎的交付选择，价格更具竞争力。零售药局很受欢迎，可以购买治疗糖尿病神经病变的药物和非处方补充品。零售药局的优势在于能够与药剂师面对面，获得个人化建议和药物管理支持，并可以获得多种产品。

区域洞察

由于糖尿病患者数量不断增加以及对该疾病的认识不断增强，美洲成为糖尿病神经病变的重要市场。 FDA 对新产品开发的核准以及开发新的有效药物的持续研究工作是美洲地区的主要成长要素。由于药物开发的研发活动活性化，亚太地区代表了全球糖尿病神经病变市场的成长。在亚太地区，有几家新兴企业专注于开发糖尿病神经病变治疗药物，为市场成长做出了贡献。政府加强支持力度，提高人们对糖尿病管理的认识，以及用于缓解疼痛和有效管理糖尿病神经病变病变症状的新药物和系统的研发，这将导致欧洲、中东和非洲地区糖尿病神经病变病变药物和系统的供应量增加，这提供了巨大的扩张潜力。此外，创新治疗方法和药物传输系统的引入预计将有助于糖尿病神经病变市场的全球成长。

FPNV定位矩阵

FPNV定位矩阵对于评估糖尿病神经病变市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对糖尿病神经病变市场供应商的现状进行深入而详细的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

该报告对以下几个方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4.竞争力评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.糖尿病神经病变市场的市场规模与预测为何？

2.在糖尿病神经病变市场的预测期内，有哪些产品、细分市场、应用和领域需要考虑投资？

3.糖尿病神经病变市场的技术趋势与法规结构是什么？

4.糖尿病神经病变市场主要供应商的市场占有率为何？

5. 进入糖尿病神经病变市场合适的型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 糖尿病神经病变的盛行率和有效治疗方法的需求
      • 提高对糖尿病诊断和治疗的认识
      • 政府管理糖尿病神经病变的倡议
    • 抑制因素
      • 临床试验失败率高，治疗费用高
    • 机会
      • 扩大糖尿病神经病变的研究领域
      • 先进药物输送系统的开发
    • 任务
      • 与糖尿病神经病变治疗相关的併发症
  • 市场区隔分析
    • 治疗类型：药物治疗广泛使用药物来缓解疼痛、稳定神经功能
    • 疾病类型：週边神经病变盛行率增加有利于糖尿病神经病变
    • 通路：网路药局的出现成为便捷的医疗药品通路
  • 市场趋势分析
    • 继续研究开发新治疗方法并提高美洲糖尿病神经病变管理系统的核准
    • 亚太地区糖尿病盛行率不断上升，专注于开发治疗方法和设备的新兴企业数量不断增加
    • 政府支持措施改善欧洲、中东和非洲地区的糖尿病治疗和护理
  • 俄罗斯-乌克兰衝突的累积影响
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法规结构分析

第六章依治疗类型分類的糖尿病神经病变市场

  • 药品
  • 物理治疗

第七章依疾病类型分類的糖尿病神经病变市场

  • 自主神经病变
  • 局部神经病变
  • 週边神经病变
  • 近端神经病变

第八章糖尿病神经病变市场：依通路

  • 诊所
  • 医院
  • 网路药房
  • 零售药房

第九章北美及南美糖尿病神经病变市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区糖尿病神经病变市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲的糖尿病神经病变市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Neuralace Medical 完成疼痛性糖尿病神经病变标籤扩展研究 (AT-PDN) 的註册，为 FDA 批准和突破性糖尿病神经病变疼痛非侵入性治疗铺平道路
    • 拨款 140 万英镑用于开发糖尿病週边神经病变的早期检测
    • Horizo​​n Therapeutics核准FDA 批准更新 TEPEZZA (teprotumumab-TRBW) 的适应症语言，以指定在甲状腺眼病 (TED) 患者中的使用，无论疾病活动度或持续时间如何。
    • Praetego 获得美国国家眼科研究所 30 万美元资助，用于开发治疗糖尿病视网膜病变的新型口服药物
    • Abbott、 Medtronic和 Nebro 正在开发 SCS 疗法来治疗週边神经病变。

糖尿病患者 对于糖尿病患者

    • NeuroMetrix 推出週边神经病变测试 DPNCheck 2.0
    • Tandem Diavites Care 完成对胰岛素帮浦製造商 AMF Medical 的收购
    • 宝洁健康 (P&G Health) 与 IDF 合作解决糖尿病患者的周边神经病变
    • Glenmark Pharma 推出治疗糖尿病併发症的药物
    • Regency Pharmaceuticals 宣布完成糖尿病週边神经神经病变2 期试验的入组工作，并获得 930 万美元的 B 系列资金筹措。
    • 医疗科技Start-UpsYostra Labs 已筹集 40 亿卢比种子轮资金，用于帮助患有慢性病的患者。
    • FDA核准PENS 装置治疗糖尿病週边神经病变相关疼痛
    • FDA核准Medtronic神经刺激设备治疗糖尿病週边神经病变疼痛
    • RMH 与澳洲糖尿病创新加速器中心合作
    • Withings 收购医疗设备製造商 Impet Medical

第13章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-4348D129FA14

[181 Pages Report] The Diabetic Neuropathy Market size was estimated at USD 3.50 billion in 2023 and expected to reach USD 3.72 billion in 2024, at a CAGR 6.37% to reach USD 5.40 billion by 2030.

Diabetic neuropathy is a medical condition that damages the nerve and occurs in patients who have diabetes. High blood sugar (glucose) can damage nerves throughout the body, and diabetic neuropathy most frequently impacts nerves in the legs and feet. The increasing need for effective treatment for diabetic neuropathy, diagnosis of diabetes, and several government initiatives are the major driving factors for the growth of the diabetic neuropathy market. In addition, the growing awareness about diabetic neuropathy, increased healthcare spending, and a rise in pharmaceutical R&D spending contribute to developing novel drugs and systems for treating diabetic neuropathy. However, the high cost of medications used to treat diabetic neuropathy and the availability of alternative therapies may limit their use by diabetic patients. Production of advanced drug delivery systems and rising research in diabetic neuropathy are leading to the development of a breakthrough system for the effective management of diabetic neuropathy conditions, accelerating their use by patients in the forecast period.

KEY MARKET STATISTICS
Base Year [2023] USD 3.50 billion
Estimated Year [2024] USD 3.72 billion
Forecast Year [2030] USD 5.40 billion
CAGR (%) 6.37%

Treatment Type: Wide use of drugs for pharmacological treatment in diabetic neuropathy for alleviating pain and stabilizing nerve function

Drugs are used in the pharmacological treatment of diabetic neuropathy for alleviating pain and stabilizing nerve function. Pregabalin (Lyrica) and gabapentin (Neurontin) are popular anticonvulsant drugs for managing nerve pain in diabetic neuropathy patients. Among opioids, Tramadol (Ultram) is a centrally-acting opioid analgesic prescribed for moderate to severe pain associated with diabetic neuropathy. Physiotherapy, also known as physical therapy, is a non-pharmacological treatment that can help diabetic neuropathy patients improve their functional abilities and alleviate pain. Regular exercise and strengthening programs supervised by a certified physiotherapist can help improve muscle strength, balance, and endurance in diabetic neuropathy patients. Physiotherapy is often preferred to avoid side effects or contraindications.

Disorder Type: Preference for diabetic neuropathy due to increasing prevalence of peripheral neuropathy

Autonomic neuropathy affects the autonomic nervous system, which controls the involuntary functions of internal organs. Patients with this condition experience irregular heartbeat, urinary problems, digestive issues, and sexual dysfunction. Based on individual needs, treatments include medications to regulate blood pressure and heart rate, drugs for gastrointestinal motility, and medications to treat erectile dysfunction. Focal neuropathy is a disorder that affects a single nerve or group of nerves, causing severe pain or weakness localized in specific body parts such as hands, feet, or torso. The treatment addresses the underlying cause, such as compression or entrapment, including splinting or bracing for carpal tunnel syndrome or surgical intervention for severe cases. Peripheral neuropathy is the most common type, affecting the nerves of arms, hands, legs, and feet. Symptoms include numbness, tingling, pain, and weakness. Treatment preferences depend on individual needs, including over-the-counter pain relievers and prescription medications. Proximal neuropathy primarily affects the hip, buttock, or thigh muscles with symptoms such as severe pain and muscle weakness.

Distribution channel: Emergence of online pharmacies as a convenient distribution channel for medications prescribed for diabetic neuropathy management

Patients with diabetic neuropathy prefer clinics for convenience, affordability, and accessibility as they provide specialized care through a team of experts, including endocrinologists, podiatrists, and diabetes educators. Hospitals serve as comprehensive care providers for diabetic neuropathy patients requiring more extensive treatment or emergency interventions due to severe complications such as infections or ulcers. They offer access to equipment and multidisciplinary teams with expertise in treating complex cases. Online pharmacies have emerged as a convenient distribution channel for medications prescribed for diabetic neuropathy management, such as pain relievers, anti-seizure medications, and antidepressants. Patients prefer online pharmacies due to their ease of use, discreet delivery options, and competitive pricing compared to retail pharmacies. Retail pharmacies are popular for obtaining medications and over-the-counter supplements to manage diabetic neuropathy. They offer the advantage of face-to-face interaction with pharmacists who can provide personalized advice, medication management support, and access to a wide range of products.

Regional Insights

The Americas has a significant market in diabetic neuropathy due to the presence of a rising number of diabetic patients and increasing awareness related to diabetes disorders. Approvals from the FDA for new product development and ongoing research activities for developing novel and effective drugs are major growth factors in the Americas region. The Asia-Pacific region represents a growing landscape for the global diabetic neuropathy market due to increasing R&D activities in drug development. Several start-ups focusing on developing diabetic neuropathy treatments in the APAC region have contributed to the market growth. Government support to raise awareness regarding diabetes management and increased research and development of novel drugs and systems for relieving pain and efficient management of diabetic neuropathy conditions are creating the immense potential for the deployment of diabetic neuropathy drugs and systems in the EMEA region. Additionally, the introduction of innovative treatments and drug delivery systems is expected to contribute to the growth of the diabetic neuropathy market worldwide.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Diabetic Neuropathy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Diabetic Neuropathy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Diabetic Neuropathy Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AdventHealth, Alkem Labs, Astellas Pharma Inc., AstraZeneca PLC, Bauerfeind AG, Bayer AG, Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Collegium Pharmaceutical, Inc., Daiichi Sankyo Company, Limited, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Glenmark Pharmaceuticals Limited, Grunenthal GmbH, Harmonium Pharma s.r.l., Lupin Limited, Medtronic PLC, Merck KGaA, NeuroMetrix, Inc., Nevro Corp., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Praetego, LLC, Regenacy Pharmaceuticals, Inc., Sanofi S.A., Stem Cell Care India, Teva Pharmaceutical Industries Ltd., The Procter & Gamble Company, Trevena, Inc., Vertex Pharmaceuticals Incorporated, Viatris Inc., and Winsantor, Inc..

Market Segmentation & Coverage

This research report categorizes the Diabetic Neuropathy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Treatment Type
    • Drugs
      • Analgesics
        • Non-Steroidal Anti-Inflammatory Drugs
        • Opioids
        • Topical
      • Anticonvulsants
        • Gabapentin
        • Pregabalin
        • Topiramate
      • Antidepressant
        • Serotonin & Norepinephrine Reuptake Inhibitors
        • SSRIs
        • TCAs
    • Physiotherapy
  • Disorder Type
    • Autonomic Neuropathy
    • Focal Neuropathy
    • Peripheral Neuropathy
    • Proximal Neuropathy
  • Distribution channel
    • Clinics
    • Hospitals
    • Online Pharmacy
    • Retail Pharmacy
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Diabetic Neuropathy Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Diabetic Neuropathy Market?

3. What are the technology trends and regulatory frameworks in the Diabetic Neuropathy Market?

4. What is the market share of the leading vendors in the Diabetic Neuropathy Market?

5. Which modes and strategic moves are suitable for entering the Diabetic Neuropathy Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of diabetic neuropathy and the need for effective treatment methods
      • 5.1.1.2. Increasing awareness pertaining to diagnosis & treatment of diabetes
      • 5.1.1.3. Government initiatives for the management of diabetic neuropathy
    • 5.1.2. Restraints
      • 5.1.2.1. High failure rate in clinical trials and high cost of diabetic neuropathy treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Widening diabetic neuropathy research areas
      • 5.1.3.2. Development of advanced drug delivery systems
    • 5.1.4. Challenges
      • 5.1.4.1. Complications associated with diabetic neuropathy treatment
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Type: Wide use of drugs for pharmacological treatment in diabetic neuropathy for alleviating pain and stabilizing nerve function
    • 5.2.2. Disorder Type: Preference for diabetic neuropathy due to increasing prevalence of peripheral neuropathy
    • 5.2.3. Distribution channel: Emergence of online pharmacies as a convenient distribution channel for medications prescribed for diabetic neuropathy management
  • 5.3. Market Trend Analysis
    • 5.3.1. Ongoing research for the development of novel treatments and rise in approvals for diabetic neuropathy management systems in the Americas
    • 5.3.2. Increasing prevalence of diabetes and emerging start-ups focused on developing diabetic neuropathy treatments and devices in the APAC region
    • 5.3.3. Supportive government initiatives to improve diabetes disease treatment and care in the EMEA region
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework Analysis

6. Diabetic Neuropathy Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Drugs
  • 6.3. Physiotherapy

7. Diabetic Neuropathy Market, by Disorder Type

  • 7.1. Introduction
  • 7.2. Autonomic Neuropathy
  • 7.3. Focal Neuropathy
  • 7.4. Peripheral Neuropathy
  • 7.5. Proximal Neuropathy

8. Diabetic Neuropathy Market, by Distribution channel

  • 8.1. Introduction
  • 8.2. Clinics
  • 8.3. Hospitals
  • 8.4. Online Pharmacy
  • 8.5. Retail Pharmacy

9. Americas Diabetic Neuropathy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Diabetic Neuropathy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Diabetic Neuropathy Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Neuralace Medical Completes Enrollment of Painful Diabetic Neuropathy Label Expansion Study (AT-PDN) Paving the Way for FDA Clearance and a Breakthrough, Non-invasive Treatment for Diabetes related Neuropathic Pain
    • 12.3.2. GBP 1.4 million Awarded to Create early test for Diabetic Peripheral Neuropathy
    • 12.3.3. Horizon Therapeutics PLC announced FDA approval of an update to the indication language for TEPEZZA (teprotumumab-trbw) to specify its use in thyroid eye disease (TED) patients regardless of disease activity or duration
    • 12.3.4. Praetego awarded USD 300,000 by National Eye Institute to advance novel oral drug for diabetic retinopathy
    • 12.3.5. Abbott, Medtronic, and Nevro are developing SCS therapies to treat peripheral neuropathy treatment

a diabetic for diabetic

    • 12.3.6. NeuroMetrix launched peripheral neuropathy test DPNCheck 2.0
    • 12.3.7. Tandem Diabetes Care completed acquisition of insulin pump maker AMF Medical
    • 12.3.8. P&G Health, IDF partnered to address Peripheral Neuropathy in people with diabetes
    • 12.3.9. Glenmark Pharma launched drug for diabetic patients with comorbidities
    • 12.3.10. Regenacy Pharmaceuticals announced the completion of enrollment for phase 2 Study in diabetic peripheral neuropathy & USD 9.3 million series B financing
    • 12.3.11. Medtech startup Yostra Labs raised Rs 4Cr in a Seed round to help patients suffering from chronic disease
    • 12.3.12. FDA Clears PENS Device for pain related to diabetic peripheral neuropathy
    • 12.3.13. FDA cleared Medtronic's neurostimulator for diabetic peripheral neuropathy pain
    • 12.3.14. The RMH partnered with Australian Centre for Accelerating Diabetes Innovations
    • 12.3.15. Withings acquired Devicemaker Impeto Medical

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. DIABETIC NEUROPATHY MARKET RESEARCH PROCESS
  • FIGURE 2. DIABETIC NEUROPATHY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. DIABETIC NEUROPATHY MARKET DYNAMICS
  • FIGURE 7. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. DIABETIC NEUROPATHY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. DIABETIC NEUROPATHY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DIABETIC NEUROPATHY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY OPIOIDS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TOPICAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TOPICAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY GABAPENTIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY GABAPENTIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY PREGABALIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY PREGABALIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TOPIRAMATE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TOPIRAMATE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY SEROTONIN & NOREPINEPHRINE REUPTAKE INHIBITORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY SEROTONIN & NOREPINEPHRINE REUPTAKE INHIBITORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY SSRIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY SSRIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TCAS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TCAS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY AUTONOMIC NEUROPATHY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY AUTONOMIC NEUROPATHY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY FOCAL NEUROPATHY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY FOCAL NEUROPATHY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY PERIPHERAL NEUROPATHY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY PERIPHERAL NEUROPATHY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY PROXIMAL NEUROPATHY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY PROXIMAL NEUROPATHY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 66. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 69. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 70. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 71. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 72. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 73. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 74. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 75. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 76. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 77. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 78. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 79. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 80. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 81. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 84. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 85. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 86. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 87. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 88. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 89. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 90. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 91. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 92. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 93. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 94. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 95. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 96. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 97. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 98. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 99. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 100. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 101. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 102. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 103. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 104. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 105. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 108. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 109. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 110. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 111. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 112. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 113. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 114. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 115. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 116. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 117. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 118. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 119. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 122. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 123. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 124. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 125. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 126. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 127. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 128. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 129. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 130. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 131. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 132. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 133. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 136. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 137. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 140. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 141. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 142. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 143. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 144. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 145. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 146. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 147. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 150. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 151. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 152. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 169. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 172. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 173. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 174. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 175. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 176. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 177. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 178. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 179. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 180. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 181. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 182. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 183. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 184. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 185. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 186. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 187. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 188. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 189. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 190. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 191. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 192. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 193. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 196. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 197. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 200. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 201. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 202. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 203. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 204. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 205. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 206. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 207. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 208. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 209. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 210. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 211. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 212. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 213. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 214. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 215. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 216. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 217. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 218. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 219. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 220. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 221. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 222. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 223. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 224. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 225. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 226. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 227. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 228. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 229. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 230. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 231. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 232. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 233. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 234. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 235. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 238. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 239. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 240. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 241. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 242. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 243. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 244. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 245. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 246. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 247. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 248. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 249. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 252. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 253. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 254. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 255. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 256. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 257. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 258. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 259. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 260. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 261. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 262. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 263. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 264. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 265. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 266. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 267. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 268. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 269. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 270. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 271. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 272. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 273. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 274. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 275. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 276. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 277. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 280. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 281. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 282. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 283. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 284. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 285. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 286. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 287. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 288. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 289. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 290. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 291. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 292. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 293. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 294. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 295. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 296. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 297. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 298. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 299. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 300. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 301. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 302. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 303. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 304. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 305. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 306. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 307. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 308. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 309. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 310. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 311. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 312. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 313. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 314. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 315. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 316. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 317. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 318. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 319. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 320. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 321. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 322. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 323. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 324. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 325. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 326. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 327. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 328. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 329. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 330. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 331. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 332. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 333. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 334. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 335. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 336. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 337. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 338. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 339. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 340. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 341. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 342. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MIL